Amylyx Pharmaceuticals (AMLX) Insider Trading & Ownership $7.64 -0.20 (-2.55%) Closing price 04:00 PM EasternExtended Trading$7.58 -0.06 (-0.85%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Amylyx Pharmaceuticals (NASDAQ:AMLX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage11.70%Number OfInsiders Buying(Last 12 Months)3Amount OfInsider Buying(Last 12 Months)$358.20KNumber OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$348.87K Get AMLX Insider Trade Alerts Want to know when executives and insiders are buying or selling Amylyx Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address AMLX Insider Buying and Selling by Quarter Amylyx Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/31/2025Camille L BedrosianInsiderSell12,425$3.47$43,114.75 3/31/2025James M FratesCFOSell10,896$3.47$37,809.12 3/31/2025Joshua B CohenCEOSell21,490$3.47$74,570.30 3/20/2025Bernhardt G ZeiherDirectorBuy10,000$3.70$37,000.00 2/24/2025Gina MazzarielloInsiderSell4,169$3.15$13,132.35 2/3/2025Gina MazzarielloInsiderSell3,678$3.49$12,836.22 2/3/2025Joshua B CohenCEOSell11,851$3.47$41,122.97 1/6/2025Justin B KleeCEOSell7,471$4.04$30,182.84 9/30/2024Camille L BedrosianInsiderSell11,442$3.20$36,614.40 9/30/2024Justin B KleeCEOSell18,589$3.20$59,484.80 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 9/12/2024James M FratesCFOBuy40,000$2.53$101,200.00 9/3/2024George M Milne JrDirectorBuy100,000$2.20$220,000.00 (Data available from 1/1/2013 forward) AMLX Insider Trading Activity - Frequently Asked Questions Who is on Amylyx Pharmaceuticals' Insider Roster? The list of insiders at Amylyx Pharmaceuticals includes Bernhardt G Zeiher, Camille L Bedrosian, Daphne Quimi, George M Milne Jr, Gina Mazzariello, Global Investors Lp Viking, James M Frates, Joshua B Cohen, Justin B Klee, Morningside Venture Investment, and Patrick D Yeramian. Learn more on insiders at AMLX. What percentage of Amylyx Pharmaceuticals stock is owned by insiders? 11.70% of Amylyx Pharmaceuticals stock is owned by insiders. Learn more on AMLX's insider holdings. Which Amylyx Pharmaceuticals insiders have been buying company stock? The following insiders have purchased AMLX shares in the last 24 months: Bernhardt G Zeiher ($37,000.00), Daphne Quimi ($5,197.50), George M Milne Jr ($220,000.00), and James M Frates ($101,200.00). How much insider buying is happening at Amylyx Pharmaceuticals? Insiders have purchased a total of 152,750 AMLX shares in the last 24 months for a total of $363,397.50 bought. Which Amylyx Pharmaceuticals insiders have been selling company stock? The following insiders have sold AMLX shares in the last 24 months: Camille L Bedrosian ($79,729.15), Gina Mazzariello ($127,709.05), James M Frates ($115,725.56), Joshua B Cohen ($193,141.82), Justin B Klee ($185,051.17), and Patrick D Yeramian ($45,919.96). How much insider selling is happening at Amylyx Pharmaceuticals? Insiders have sold a total of 134,140 Amylyx Pharmaceuticals shares in the last 24 months for a total of $747,276.71 sold. Amylyx Pharmaceuticals Key ExecutivesMr. Joshua B. Cohen (Age 32)Co-Founder, Co-CEO & Director Compensation: $1.08M1 recent tradesMr. Justin B. Klee (Age 33)Co-Founder, Co-CEO & Director Compensation: $1.08MMr. James M. Frates M.B.A. (Age 57)Chief Financial Officer Compensation: $763.16k1 recent tradesMs. Gina M. Mazzariello (Age 53)Chief Legal Officer & General Counsel Compensation: $689.26k1 recent tradesDr. Camille L. Bedrosian M.D. (Age 71)Chief Medical Officer Compensation: $232.6k1 recent tradesMr. Tom HolmesChief Technical Operations OfficerLindsey AllenHead of Investor Relations & CommunicationsMs. Shauna HorvathHead of Global MarketingMs. Linda A. ArsenaultChief Human Resources OfficerMr. Chris AielloHead of Canada & GM More Insider Trading Tools from MarketBeat Related Companies CRNX Insider Ownership NAMS Insider Ownership GMTX Insider Ownership RARE Insider Ownership OGN Insider Ownership RXRX Insider Ownership AMRX Insider Ownership MIRM Insider Ownership BHC Insider Ownership CPRX Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (NASDAQ:AMLX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opport...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
